Eli Lilly remains a buy after Q2, with robust revenue growth and strong performance from Mounjaro and Zepbound. LLY raised 2026 revenue guidance to $85–87 billion, driven by volume gains despite price ...

Eli Lilly (NYSE: LLY) is scheduled to report second-quarter results before the market opens on Wednesday, Aug. 5, with investors looking for another strong quarter driven by continued demand for its ...

While construction on the work included in the filings is projected to be completed by the end of 2027, Lilly representatives said the overall project remains on track to be completed by 2030. "Lilly ...

Male chimpanzees were more likely to exchange friendly touches with other males—like Little Jake and Little Joey shown here. Jake Brooker / Chimfunshi Wildlife Orphanage Trust From hugs and handshakes ...

Goldman is bracing for a weak first quarter of Foundayo sales, but that isn’t the number it thinks will move LLY stock on August 5.

As a legal battle brews between Eli Lilly and Novo Nordisk, Wall Street is tuning into an even bigger story.

Novo, Lilly are battling for dominance in the obesity drug market Lilly denies any wrongdoing, stands by its advertising Novo says Lilly ads use 'outdated studies' Novo seeks injunction requiring ...

Eli Lilly LLY3.90%increase; up pointing triangle is preparing application materials for its next-generation weight-loss drug, retatrutide, following data from two Phase 3 trials showing the treatment ...

Overweight or obese diabetes patients had 20.8% weight loss at high dose of retatrutide Patients with severe obesity and cardiovascular disease had weight loss of 22.6% at highest dose Lilly plans FDA ...

Eli Lilly said it will file for approval of its next-generation obesity drug, retatrutide, in the first quarter of 2027, as it succeeds in two more late-stage trials. The drug delivered significant ...